Hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B: The multicentre, prospective CAP-Asia study

Leow YW 1 , Chan WK 1 , Goh GB 2 , Wong VW 3 , Fan JG 4 , Kim YS 5 Show all authors , Kim SU 6 , Nakajima A 7 , Seto WK 8 , Lee IC 9 , Huang YH 9 , Kim YJ 10 , Young JJ 11 , Chow WC 2

Affiliations 

  • 1 Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 2 Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore, Singapore
  • 3 Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong
  • 4 Department of Gastroenterology and Hepatology, Shanghai Jiaotong University School of Medicine Xinhua Hospital, Shanghai, China
  • 5 Division of Gastroenterology and Hepatology, Department of Internal Medicine, SoonChunHyang University, Bucheon Hospital, Bucheon-si, Korea
  • 6 Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Seoul, Korea
  • 7 Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
  • 8 Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, Hong Kong
  • 9 Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
  • 10 Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea
  • 11 Soon Chun Hyang University Seoul Hospital, Seoul, Korea
J Viral Hepat, 2023 Apr;30(4):319-326.
PMID: 36606597 DOI: 10.1111/jvh.13796

Abstract

We aimed to compare the severity of liver disease, metabolic profile and cardiovascular disease (CVD) risk of chronic hepatitis B (CHB) patients with and without hepatic steatosis and patients with non-alcoholic fatty liver disease (NAFLD). Patients with NAFLD and CHB were prospectively enrolled from 10 Asian centres. Fibroscan was performed for all patients and hepatic steatosis was defined based on controlled attenuation parameter >248 dB/m. CVD risk was assessed using the Framingham risk score. The data for 1080 patients were analysed (67% NAFLD, 33% CHB). A high proportion (59%) of CHB patients had hepatic steatosis. There was a significant stepwise increase in alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, controlled attenuation parameter and liver stiffness measurement, from CHB patients without hepatic steatosis to CHB patients with hepatic steatosis to NAFLD patients (p 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications